This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.
Categorical data presented as n (%), continuous data presented as mean (SD). The p-values can be used to identify the statistically, but not necessarily clinically, significant differences between patients in IST-3 and patients in the 8 earlier trials.
Page 1 of 5 Webfigure 2: Effect of alteplase on a good stroke outcome (mRS 0−1) by treatment delay, age and stroke severity
The solid line on each plot represents the interaction between alteplase with one of time, age or baseline NIHSS. Each is adjusted for treatment delay (linear), age (linear) and baseline NIHSS (quadratic), and interactions between alteplase with the other main effects (i.e. two of age, time and baseline NIHSS).
The estimated odds ratio is plotted for patients with AVERAGE levels of the other 2 baseline characteristics. The OR for alteplase was 1.22 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours). The significance of each interaction is tested by comparing the change in deviance between two nested models that differ only by the interaction term(s) (ie, the likelihood ratio test). SDs from mean
